Thromboembolic outcomes after use of a four‐factor prothrombin complex concentrate for vitamin K antagonist reversal in a real‐world setting

Abstract

This study supports the safety of 4F-PCC for urgent VKA reversal even in unselected patients. The underlying type of hypercoagulable state and the dose of PCC may influence the incidence of TEE.